Good luck to you too. Not sure why you would pull your investment as soon as the company is actually making progress, but I guess you need the money...
As for the claims about FCSC not reporting income in 3Q and therefore something is wrong, this interpretation makes zero sense. How could they report income when they only rolled out in the last month of 3Q and they are not paid until the procedure is completed, which takes weeks? If you review previous posts, most (if not all) of us expected to not see any revenue reported until we receive the 4Q 2011 report in 1Q 2012 at the earliest.
laltrader did a good job highlighting the important points made on the call. I took note of most of the same updates, including:
1) The trial doctor for the acne scarring mostly reviewed his study, but the most interesting answer he gave to a question was that 80% of all treatment in dermatology is off-label. He said he would be remiss not to mention to a patient with acne scarring that LaViv was available, even before FDA formally approves it. He also said LaViv probably would receive a favorable view from the FDA on pursuing the indication for acne due to it being such a large problem. For the naysayers (Dew), you've tried to make a big point about the fact that FCSC will be bankrupt before they ever get acne treatment off the ground and there is still a long way to go to meet approval from the FDA, but based upon the evidence this doctor provided, looks like it really won't matter because they'll be using it off-label until they get approval anyways.
2) Should hear from FDA on orphan drug status for burn/vocal chord scarring in "weeks".
3) Personalized skin cream available in 1Q 2012.
4) To date, 154 doctors received certification to provide LaViv with 60 doctors trained in the last week alone. Expect to have 270 doctors trained by the end of the year.
5) 105 biopsies in progress. "Not much" revenue being generated from these biopsies as the doctors are receiving the product at a lower rate to build momentum for the product.
6) At national dermatology conference, only 3 products were offered a "Hot Topic" session. The LaViv session was standing room only, while the other 2 products that were given a session were not nearly as well attended.
7) Finally, someone asked a question on financing, but Pernock did not give much insight. Only that "all offers were on the table."
8) Lots more publicity coming down the pipeline.
9) Feel that their IP is well protected, but filed for patent extension. Will hear whether they are approved early-mid next year.
My overall interpretation is that I am excited to see how many doctors are getting onboard and am encouraged by the progress. It sounds like there could be some more good news before the end of the year. As I said a couple of months ago, I'm not expecting much in the way of results until after mid next year, but I'm comfortable with my investment. I've thought about investing more, but my only concern right now is financing.
My posts are just my own opinions. Do your own DD.
AI
